LU91709I2 - Roflumilast, roflumilast-N-oxyde et les sels de ces composés - Google Patents

Roflumilast, roflumilast-N-oxyde et les sels de ces composés

Info

Publication number
LU91709I2
LU91709I2 LU91709C LU91709C LU91709I2 LU 91709 I2 LU91709 I2 LU 91709I2 LU 91709 C LU91709 C LU 91709C LU 91709 C LU91709 C LU 91709C LU 91709 I2 LU91709 I2 LU 91709I2
Authority
LU
Luxembourg
Prior art keywords
stands
alkoxy
halogen
hydrogen
alkyl
Prior art date
Application number
LU91709C
Other languages
English (en)
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4223466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91709(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of LU91709I2 publication Critical patent/LU91709I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
LU91709C 1993-07-02 2010-07-21 Roflumilast, roflumilast-N-oxyde et les sels de ces composés LU91709I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH199693 1993-07-02
PCT/EP1994/002169 WO1995001338A1 (fr) 1993-07-02 1994-07-02 Nouveaux benzamides a substituants fluoroalcoxy et leur utilisation comme inhibiteurs de la phosphodiesterase nucleotidique cyclique

Publications (1)

Publication Number Publication Date
LU91709I2 true LU91709I2 (fr) 2010-09-21

Family

ID=4223466

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91709C LU91709I2 (fr) 1993-07-02 2010-07-21 Roflumilast, roflumilast-N-oxyde et les sels de ces composés

Country Status (27)

Country Link
US (1) US5712298A (fr)
EP (1) EP0706513B1 (fr)
JP (1) JP3093271B2 (fr)
KR (1) KR100331255B1 (fr)
CN (1) CN1046939C (fr)
AT (1) ATE217612T1 (fr)
AU (1) AU687087B2 (fr)
CA (1) CA2165192C (fr)
CY (2) CY2389B1 (fr)
CZ (1) CZ290266B6 (fr)
DE (2) DE59410119D1 (fr)
DK (1) DK0706513T3 (fr)
ES (1) ES2176252T3 (fr)
FI (1) FI112864B (fr)
FR (1) FR10C0052I2 (fr)
HU (1) HU220041B (fr)
LU (1) LU91709I2 (fr)
LV (1) LV13074B (fr)
NO (2) NO305598B1 (fr)
NZ (1) NZ271316A (fr)
PL (1) PL178314B1 (fr)
PT (1) PT706513E (fr)
RU (1) RU2137754C1 (fr)
SG (1) SG143011A1 (fr)
SI (1) SI0706513T1 (fr)
SK (1) SK283263B6 (fr)
WO (1) WO1995001338A1 (fr)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US6096768A (en) * 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
WO1998007715A1 (fr) * 1996-08-19 1998-02-26 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouveaux benzofuran-4-carboxamides
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1998019672A1 (fr) * 1996-11-01 1998-05-14 Nitromed Inc. Composes nitroses et nitrosyles inhibiteurs de la phosphodiesterase, compositions comprenant ces composes et utilisations correspondantes
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
DE69835594T2 (de) * 1997-02-17 2007-08-16 Altana Pharma Ag Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6118017A (en) * 1998-04-14 2000-09-12 Smithkline Beecham Corporation Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one
PT1161239E (pt) * 1999-03-10 2005-02-28 Altana Pharma Ag 3-ciclopropilmetoxi-4-difluorometoxi-n-(3,5-dicloropirid-4-il)-benzamida para o tratamento da esclerose multipla
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
CA2372850C (fr) * 1999-05-04 2011-01-18 Ulrich Kilian Combinaison synergetique comprenant du roflumilast et un inhibiteur pde3
EP1212089B1 (fr) * 1999-08-21 2006-03-22 ALTANA Pharma AG Combinaison synergetique de roflumilast et salmeterol
AU2001261962B2 (en) * 2000-05-25 2005-04-21 Merck Frosst Canada Ltd Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
DE10043074A1 (de) 2000-09-01 2002-03-14 Aventis Cropscience Gmbh Herbizid wirksame Benzoylcyclohexandione
EP1199074A1 (fr) * 2000-09-15 2002-04-24 Warner-Lambert Company Composition pharmaceutique pour la prévention ou le traitement de maladies associées à un excès de production d' IL-12
EP1188438A1 (fr) * 2000-09-15 2002-03-20 Warner-Lambert Company Compositions pharmaceutiques pour la prévention ou le traitement de maladies associées à un excès de production de l' IL-12
AU2002227123A1 (en) * 2000-11-07 2002-05-21 Merck And Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7205320B2 (en) * 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
JP4460221B2 (ja) 2001-05-24 2010-05-12 メルク フロスト カナダ リミテツド １−ビアリール−１，８−ナフチリジン−４−オン系ホスホジエステラーゼ−４阻害薬
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
RU2227797C2 (ru) * 2002-03-29 2004-04-27 Пермская государственная фармацевтическая академия 4-метил-2-пиридиламид тетрахлорфталевой кислоты, проявляющий гипертензивную активность
EP1506016A2 (fr) * 2002-05-07 2005-02-16 ALTANA Pharma AG Nouvelle combinaison destinee au traitement des troubles des voies aeriennes
RS95204A (sr) * 2002-05-07 2006-12-15 Altana Pharma Ag. Kombinacija za tretman oboljenja disajnih puteva
EP1505972A2 (fr) * 2002-05-16 2005-02-16 Pharmacia Corporation Methodes de traitement de maladies et de troubles respiratoires avec un inhibiteur inos selectif et un inhibiteur pde et compositions a cet effet
ME00565A (en) * 2002-05-28 2011-12-20 Topically applicable pharmaceutical preparation
EP1539697A1 (fr) 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Inhibiteurs de phosphodiesterase 4 comprenant des analogues de diphenylamine et d'aniline n-substitues
RU2354648C2 (ru) 2002-07-19 2009-05-10 Мемори Фармасьютиклз Корпорейшн Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
WO2004022536A1 (fr) * 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited Nouveaux composes amides heterocycliques utilises pour le traitement d'affections inflammatoires et allergiques; procede permettant de les fabriquer et compositions pharmaceutiques les contenant
US20060019932A1 (en) * 2002-09-06 2006-01-26 Mancini Joseph A Treatment of rheumatoid arthritis by inhibition of pde4
CA2497977A1 (fr) * 2002-09-20 2004-04-01 Alcon, Inc. Utilisation d'inhibiteurs de la synthese des cytokines dans le traitement des troubles associes a la keratoconjonctivite seche
US6822114B1 (en) * 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
EA010408B1 (ru) 2002-10-23 2008-08-29 Гленмарк Фармасьютикалс Лтд. Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы
AU2003295656B2 (en) * 2002-11-19 2010-11-11 Memory Pharmaceuticals Corporation Pyridine N-oxide compounds as phosphodiesterase 4 inhibitors
PL216752B1 (pl) * 2002-11-27 2014-05-30 Nycomed Gmbh Środek leczniczy do zapobiegania objawom lub do leczenia chorób dróg oddechowych u ludzi i zastosowanie
TW200426138A (en) * 2002-12-10 2004-12-01 Hoffmann La Roche Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PT1606261E (pt) 2003-03-10 2010-01-11 Nycomed Gmbh Novo processo para a preparação de roflumilast
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
OA13154A (en) 2003-04-11 2006-12-13 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them.
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
WO2004098597A1 (fr) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition contenant du roflumilast et du shuil-1r ii
WO2004098598A1 (fr) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition contenant du roflumilast et un antagoniste tnf $g(a)
WO2004098596A1 (fr) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprenant roflumilast et il-1 trap
WO2004098595A1 (fr) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprenant du roflumilast et un antagoniste du tnf?
EA012279B1 (ru) 2003-05-22 2009-08-28 Никомед Гмбх Композиция, включающая ингибитор pde4 и ингибитор pde5
KR20110117731A (ko) * 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害剤
WO2005023253A1 (fr) 2003-09-05 2005-03-17 Altana Pharma Ag Utilisation d'inhibiteurs de pde4 pour le traitement du diabete sucre
WO2005026095A1 (fr) * 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Procede de preparation de roflumilast
US20070117861A1 (en) * 2003-11-12 2007-05-24 University Of South Carolina Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic-amp specific phosphodiesterase inhibitors
JPWO2005049087A1 (ja) 2003-11-20 2007-06-07 アステラス製薬株式会社 慢性骨盤痛症候群治療剤
EP1694655A2 (fr) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EP1713473B1 (fr) * 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG Combinaison d'anticholinergiques et de glucocorticoides pour le traitement prolonge de l'asthme et des broncho-pneumopathies chroniques obstructives
WO2005074982A2 (fr) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Combinaison d'anticholinergiques et d'inhibiteurs de phosphodiesterase type 4 pour le traitement de maladies respiratoires
AU2005212857B2 (en) 2004-02-18 2011-04-28 Takeda Gmbh Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (PDE) 4 inhibitors
JP2007524699A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト ロフルミラストとグリコピロニウムとの組合せ物
CN104803974A (zh) 2004-03-03 2015-07-29 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
EP1775283A4 (fr) * 2004-07-14 2008-12-10 Japan Tobacco Inc Compose 3-aminobenamide et inhibiteur d'activite a recepteur vanilloide 1 (vr1)
KR101042490B1 (ko) * 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US20080085858A1 (en) * 2004-10-13 2008-04-10 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical Composition
EP1799632A2 (fr) 2004-10-13 2007-06-27 Glenmark Pharmaceuticals S.A. Procede de preparation de n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide
WO2006041121A1 (fr) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Traitements prophylactiques ou thérapeutiques de maladie chronique de la peau
AP2334A (en) 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
CN101124229B (zh) 2004-12-17 2012-07-18 格兰马克药品股份有限公司 用于治疗炎性和过敏性障碍的新杂环化合物
WO2006094640A2 (fr) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Association de roflumilast et d'un inhibiteur de l'integrine, et procede de traitement
WO2006094942A1 (fr) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast pour le traitement du diabète sucré
AU2006222060B2 (en) * 2005-03-08 2011-09-01 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
ES2570332T3 (es) * 2005-03-16 2016-05-17 Meda Pharma Gmbh & Co Kg La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
NZ561746A (en) 2005-04-19 2011-09-30 Nycomed Gmbh Roflumilast for the treatment of pulmonary hypertension
JP2008540486A (ja) * 2005-05-11 2008-11-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物
US20090209599A1 (en) * 2005-06-09 2009-08-20 Yoko Endo Eye drop containing roflumilast
EP1928437A2 (fr) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
AU2006306240A1 (en) * 2005-10-24 2007-05-03 Novartis Ag Combination of histone deacetylase inhibitors and radiation
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2627599A1 (fr) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Procede de preparation de sel hemicalcique d'acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique
NZ591969A (en) 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
EP1991212A1 (fr) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation de neurogenèse par des agents nootropes
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2008020314A2 (fr) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Formulations de dosage stabilisantes à base de statine
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
EP2359826B1 (fr) 2006-07-05 2013-10-30 Takeda GmbH Combinaison d'un inhibiteur de la HMG-CoA reductase rosuvastatine avec un inhibiteur de la phosphodiesterase 4, tel que roflumilast, roflumilast-N-oxyde, pour le traitement de maladies pulmonaires inflammatoires
US20080153896A1 (en) * 2006-07-14 2008-06-26 Gyan Chand Yadav Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
JPWO2008026687A1 (ja) 2006-09-01 2010-01-21 杏林製薬株式会社 ピラゾロピリジンカルボキサミド誘導体及びそれらを含有するホスホジエステラーゼ（ｐｄｅ）阻害剤
EP2068872A1 (fr) * 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2008110891A2 (fr) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, Nouveaux dérivés hétérocycliques
KR100844125B1 (ko) * 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
CA2686909C (fr) 2007-05-16 2016-07-05 Nycomed Gmbh Derives de pyrazolone en tant qu'inhibiteurs de la pde4
EP2527360B1 (fr) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2292089A1 (fr) 2008-01-11 2011-03-09 Astellas Pharma Inc. Modèle animal ayant à la fois une douleur dans les testicules ou des actions d'inconfort en relation aux testicules et une miction fréquente
MX336946B (es) 2008-02-01 2016-02-08 Orchid Res Lab Ltd Heterociclos novedosos.
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010003084A2 (fr) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Inhibiteurs de la phosphodiestérase 4
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
EP2216327A1 (fr) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
EP2569285A1 (fr) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Dérivés quinoliniques bifonctionnels
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
SI3070091T1 (sl) 2010-06-24 2019-08-30 Leo Pharma A/S Derivati benzodioksola kot zaviralci fosfodiesteraze
CN102311382B (zh) * 2010-06-29 2014-05-21 大道隆达（北京）医药科技发展有限公司 罗氟司特的晶态及其制备方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102093194B (zh) * 2010-12-24 2014-01-08 江苏先声药物研究有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成方法
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
CN102690194B (zh) * 2011-03-24 2014-06-25 上海通远生物科技有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
CN102276522B (zh) * 2011-06-15 2013-04-17 无锡泓兴生物医药科技有限公司 一种制备罗氟司特的方法及其中间体
CN102336703B (zh) * 2011-07-20 2013-09-25 华润赛科药业有限责任公司 一种制备罗氟司特的方法
CN102351787B (zh) * 2011-08-18 2014-08-13 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特化合物
WO2013030789A1 (fr) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Forme pharmaceutique orale solide contenant un inhibiteur pde-iv faiblement soluble dans l'eau
CN102336704B (zh) * 2011-10-19 2013-04-17 丁克 一种制备罗氟司特的方法
EP2768822B1 (fr) * 2011-10-21 2017-12-06 Chiesi Farmaceutici S.p.A. Dérivés d'alcools 1-phényl-2-pyridinylalkyliques utilisés comme inhibiteurs de phosphodiestérase
CN102336705B (zh) * 2011-10-28 2013-03-27 成都苑东药业有限公司 一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法
WO2013072938A2 (fr) 2011-11-09 2013-05-23 Mylan Laboratories Ltd Procédé amélioré pour la préparation de roflumilast
WO2013081565A1 (fr) 2011-11-21 2013-06-06 Mahmut Bilgic Compositions pharmaceutiques comportant du roflumilast et de la terbutaline
WO2013077830A1 (fr) 2011-11-25 2013-05-30 Mahmut Bilgic Associations actives sur le plan synergique contenant du roflumilast et du carmotérol
WO2013084182A1 (fr) 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Composition pharmaceutique comprenant un inhibiteur de l'enzyme pde4 et un agent analgésique
CN102603623A (zh) * 2011-12-26 2012-07-25 北京赛林泰医药技术有限公司 制备高纯度罗氟司特的方法
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
WO2013131255A1 (fr) 2012-03-07 2013-09-12 Scinopharm (Changshu) Pharmaceutical, Ltd. Procédé de preparation de roflumilast
WO2014012954A1 (fr) 2012-07-18 2014-01-23 Takeda Gmbh Traitement de l'asthme sévère partiellement régulé ou non régulé
CN103630613B (zh) * 2012-08-21 2015-08-05 北大方正集团有限公司 分离并检测罗氟司特及其中间体的方法
US9321726B2 (en) * 2012-10-17 2016-04-26 Interquim, S.A. Process for preparing roflumilast
EP2948148B1 (fr) 2013-01-28 2020-07-29 Incozen Therapeutics Pvt. Ltd. Methodes pour le traitement de maladies autoimmunes, respiratoires et inflammatoires par inhalation de n-oxide de roflumilast
ES2637716T3 (es) 2013-02-04 2017-10-16 Grünenthal GmbH Nuevos compuestos de pirimidina condensados sustituidos
EP2951161A1 (fr) 2013-02-04 2015-12-09 Grünenthal GmbH Composés pyrimidines condensés 4-amino substitués en tant qu'inhibiteurs de pde4
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
TW201512189A (zh) 2013-04-16 2015-04-01 Gruenenthal Chemie 新型被取代之嘧啶縮合化合物
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
CN103304475A (zh) * 2013-06-13 2013-09-18 湖南千金湘江药业股份有限公司 苯甲酰胺化合物及其制备方法和用途
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
HUE035967T2 (hu) 2013-08-09 2018-06-28 Gruenenthal Gmbh Új helyettesített kondenzált pirimidinvegyületek
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
WO2015063669A1 (fr) 2013-10-30 2015-05-07 Wockhardt Limited Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
AR101196A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Compuestos de pirimidina sustituidos
AR101198A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas como inhibidores de pde4b
AR101197A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas
CN104130116B (zh) * 2014-08-18 2015-11-11 朱丽平 一种制备罗氟司特中间体的方法
WO2016063906A1 (fr) 2014-10-24 2016-04-28 久光製薬株式会社 Promédicament
CN104447245B (zh) * 2014-10-29 2017-06-06 成都森科制药有限公司 罗氟司特中间体、中间体制备方法及罗氟司特的制备方法
KR20170034707A (ko) 2015-09-21 2017-03-29 한미약품 주식회사 로플루밀라스트 함유 경구용 고형제제 및 그 제조방법
EP3165224A1 (fr) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Utilisation d'inhibiteurs de pde4 pour la prophylaxie et/ou la thérapie de la dyslipoproteinémie et des troubles apparentés
WO2017089347A1 (fr) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf
CN105523954B (zh) * 2016-02-05 2017-07-18 徐江平 3‑环丙甲氧基‑4‑烷氧基苯甲酰胺类磷酸二酯酶4抑制剂
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
ES3041129T3 (en) 2017-10-23 2025-11-07 Boehringer Ingelheim Int New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
JP7492918B2 (ja) 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient
BR112022015104A2 (pt) 2020-01-31 2022-09-27 Arcutis Biotherapeutics Inc Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição
WO2021213455A1 (fr) 2020-04-23 2021-10-28 浙江养生堂天然药物研究所有限公司 Combinaison de médicaments et son utilisation
CN111777550A (zh) * 2020-06-01 2020-10-16 山东希尔康泰药业有限公司 罗氟司特结晶性粉末原料药生产制备方法
EP4458414A3 (fr) 2020-12-04 2025-01-01 Arcutis Biotherapeutics, Inc. Formulation topique de roflumilast ayant des propriétés antifongiques
CN116963773A (zh) * 2021-01-21 2023-10-27 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法
WO2022169615A1 (fr) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Formulations de roflumilast à profil pharmacocinétique amélioré
JP2024506384A (ja) 2021-02-10 2024-02-13 イオリクス セラピューティクス，インコーポレーテッド ロフルミラストの眼科的送達方法
CA3231766A1 (fr) 2021-09-22 2023-03-30 Elizabeth W. JEFFORDS Methodes de traitement de maladies inflammatoires oculaires
CN118765194A (zh) 2021-12-28 2024-10-11 阿尔库缇斯生物疗法股份有限公司 局部罗氟司特气溶胶泡沫
CA3242325A1 (fr) 2021-12-28 2023-07-06 Arcutis Biotherapeutics, Inc. Mousses aerosols topiques
EP4586999A1 (fr) 2022-09-15 2025-07-23 Arcutis Biotherapeutics, Inc. Compositions pharmaceutiques de roflumilast et de solvants capables de dissoudre des quantités élevées de médicament
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
WO2025054483A1 (fr) 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Schémas posologiques utilisant des compositions topiques de roflumilast
US20250090509A1 (en) 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Methods of reducing itch using topical roflumilast compositions
WO2025265054A2 (fr) 2024-06-21 2025-12-26 Arcutis Biotherapeutics, Inc. Méthodes de traitement à l'aide de compositions topiques de roflumilast

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3308239A1 (de) * 1983-03-09 1984-09-13 Basf Ag, 6700 Ludwigshafen N-acyl-anthranilsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
DK159431C (da) * 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
JPS62158253A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンアミド誘導体
SU1512053A1 (ru) * 1988-01-29 1991-01-15 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 2-Окси-3,5-дигалоид-N-[3-хлор-4-(4-галоиднафтокси-1)-фенил]-бензамиды, обладающие активностью при экспериментальном описторхозе и гименолепидозе
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5449676A (en) * 1991-04-26 1995-09-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridazines
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
JP3634861B2 (ja) * 1992-06-15 2005-03-30 セルテック リミテッド 選択的ホスホジエステラーゼｉｖ阻害剤としての三置換フェニル誘導体
CZ14795A3 (en) * 1992-07-28 1996-07-17 Rhone Poulenc Rorer Ltd Benzene derivative containing phenyl group bound to aryl or heteroaryl fraction through an aliphatic or hetero atom containing group, process of its preparation and pharmaceutical composition containing thereof

Also Published As

Publication number Publication date
JP3093271B2 (ja) 2000-10-03
JPH08512041A (ja) 1996-12-17
RU2137754C1 (ru) 1999-09-20
CY2010015I1 (el) 2011-02-02
PT706513E (pt) 2002-10-31
FI956333A0 (fi) 1995-12-29
CN1046939C (zh) 1999-12-01
CY2010015I2 (el) 2011-02-02
CA2165192A1 (fr) 1995-01-12
WO1995001338A1 (fr) 1995-01-12
PL178314B1 (pl) 2000-04-28
HUT73232A (en) 1996-07-29
NO305598B1 (no) 1999-06-28
PL311820A1 (en) 1996-03-18
FR10C0052I2 (fr) 2011-11-25
DE59410119D1 (de) 2002-06-20
NO2010018I1 (no) 2010-10-18
NO2010018I2 (fr) 2011-10-17
SK161795A3 (en) 1996-07-03
SK283263B6 (sk) 2003-04-01
EP0706513A1 (fr) 1996-04-17
CN1126468A (zh) 1996-07-10
CY2389B1 (en) 2004-09-10
KR960703400A (ko) 1996-08-17
NO955211D0 (no) 1995-12-21
NO955211L (no) 1995-12-21
CZ196A3 (en) 1996-06-12
ES2176252T3 (es) 2002-12-01
KR100331255B1 (ko) 2002-10-25
AU7490794A (en) 1995-01-24
LV13074B (en) 2004-03-20
ATE217612T1 (de) 2002-06-15
SG143011A1 (en) 2008-06-27
CZ290266B6 (cs) 2002-06-12
AU687087B2 (en) 1998-02-19
SI0706513T1 (en) 2002-10-31
HU220041B (hu) 2001-10-28
DK0706513T3 (da) 2002-09-09
FI956333A7 (fi) 1995-12-29
DE122010000043I1 (de) 2011-01-27
CA2165192C (fr) 2001-04-24
EP0706513B1 (fr) 2002-05-15
NZ271316A (en) 1997-11-24
US5712298A (en) 1998-01-27
HU9503541D0 (en) 1996-02-28
FI112864B (fi) 2004-01-30
FR10C0052I1 (fr) 2011-01-14
HK1011690A1 (en) 1999-07-16

Similar Documents

Publication Publication Date Title
LU91709I2 (fr) Roflumilast, roflumilast-N-oxyde et les sels de ces composés
ATE236629T1 (de) Verwendung heterocyclischer verbindungen als dopamin-d 3 liganden
DK1000035T3 (da) Substituerede 6-phenylphenanthridiner
NO970161D0 (no) Triazolforbindelser og anvendelse derav
ZA954796B (en) Diamines
BR9405910A (pt) Piridinas substituídas heterocíclicas herbicidas
ATE233252T1 (de) Substituierte dihydrobenzofurane als pde- hemmstoffe
ATE249438T1 (de) Cyanoguanidine als zellproliferation inhibitoren
ATE181731T1 (de) Isothioharnstoff-derivate als no synthase hemmer
NO20064416L (no) Nye tio-inneholdende hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
JP2002534505A5 (fr)
HU9402466D0 (en) Indole derivatives as steroid-5-alpha-reductase inhibitors
ATE248819T1 (de) Cyanoguanidine als zellproliferation inhibitoren
ATE167184T1 (de) Tris-(cyanato)-s-triazine, damit erhältiche anisotrope duroplastische netzwerke
JP2003519686A5 (fr)
NO944332L (no) Substituerte pyridiner, samt fremstilling og farmasöytisk anvendelse derav
ATE181327T1 (de) Indolderivate
CA2554797A1 (fr) Derives de 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one inhibiteurs de pde4
DE69403896D1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten